REG - AstraZeneca PLC - AstraZeneca: Q1 2017 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 4
27/04/2017 07:06
- Part 4: For the preceding part double click ID:nRSa4739Dc
that AstraZeneca
misrepresented the safety profile of, and improperly promoted, Seroquel IR and Seroquel XR. The US government and the named
states have declined to intervene in this case.
Texas Attorney General litigation
In the US, in October 2014, following a previously disclosed investigation by the State of Texas into AstraZeneca's sales
and marketing activities involving Seroquel, the Texas Attorney General's Office intervened in a state whistleblower action
pending in Travis County Court, Texas. The lawsuit alleges that AstraZeneca engaged in inappropriate promotion of Seroquel
and made improper payments intended to influence the formulary status of Seroquel. The trial is scheduled for October
2017.
6 product analysis
World Emerging Markets US Europe Established ROW
Q1 2017$m Actual% CER% Q1 2017$m Actual% CER Q1 2017$m Actual% Q1 2017$m Actual% CER% Q1 2017$m Actual% CER%
%
Oncology
Tagrisso 171 n/m n/m 6 n/m n/m 90 100 35 n/m n/m 40 n/m n/m
Iressa 124 (8) (7) 61 (9) (7) 8 100 26 (24) (24) 29 (3) (3)
Lynparza 57 30 32 4 100 150 27 (4) 25 79 79 1 n/m n/m
Legacy:
Faslodex 214 13 13 27 29 24 118 19 54 (4) (2) 15 7 7
Zoladex 185 4 5 87 30 31 8 (20) 32 (18) (13) 58 (6) (8)
Casodex 56 (10) (8) 30 3 7 - - 6 (14) (14) 20 (23) (23)
Arimidex 52 (9) (7) 29 - 3 1 (75) 8 - - 14 (13) (13)
Others 26 24 24 7 - - - - 1 - - 18 38 38
Total Oncology 885 20 21 251 14 16 252 33 187 13 14 195 21 20
CVMD
Brilinta/Brilique 224 24 27 60 46 54 87 24 65 8 12 12 20 20
Farxiga/Forxiga 207 25 25 42 100 90 96 2 50 22 24 19 111 111
Onglyza 154 (27) (27) 30 (17) (17) 81 (35) 27 (18) (18) 16 (11) (11)
Bydureon 153 13 14 1 (50) - 127 18 22 (4) (4) 3 50 50
Byetta 46 (26) (24) 5 - 20 30 (29) 8 (20) (20) 3 (40) (40)
Legacy:
Crestor 631 (45) (44) 202 10 14 112 (82) 195 (8) (4) 122 (2) (4)
Seloken/Toprol-XL 186 1 3 152 9 11 11 (48) 21 (5) (5) 2 - -
Atacand 75 4 7 44 26 31 6 (33) 21 (13) (13) 4 - -
Others 103 (18) (16) 58 (29) (26) 14 180 23 (23) (23) 8 (11) (11)
Total CVMD 1,779 (22) (21) 594 9 12 564 (49) 432 (5) (3) 189 3 2
Respiratory
Symbicort 677 (10) (8) 112 7 10 255 (21) 200 (13) (9) 110 21 16
Pulmicort 337 9 14 250 21 28 41 (27) 26 (10) (7) 20 11 11
Daliresp/Daxas 44 42 42 1 n/m n/m 38 23 5 n/m n/m - - -
Tudorza/Eklira 37 (5) (3) - - - 15 (12) 20 (5) - 2 100 100
Duaklir 19 46 54 - - - - - 19 58 58 - - -
Others 67 3 6 27 (29) (24) 3 (25) 28 40 40 9 200 200
Total Respiratory 1,181 (2) - 390 11 17 352 (18) 298 (5) (1) 141 25 21
Other
Nexium 461 - 1 175 (1) 3 136 4 61 2 3 89 (6) (9)
Synagis 230 (6) (6) - - - 157 (2) 73 (13) (13) - - -
Losec/Prilosec 68 (9) (7) 35 (10) (5) 5 150 18 (14) (14) 10 (23) (23)
Seroquel XR 67 (67) (66) 15 (17) (11) 24 (83) 22 (37) (37) 6 20 20
Movantik/Moventig 30 76 76 - - - 30 76 - - - - - -
FluMist/Fluenz - (100) (100) - - - - (100) - - - - - -
Others 142 (56) (56) 102 (10) (23) (35) n/m 38 (57) (30) 37 (43) (55)
Total Other 998 (25) (24) 327 (2) (3) 317 (39) 212 (5) (1) 142 (2) (3)
TOTAL PRODUCT SALES 4,843 (13) (12) 1,562 7 9 1,485 (34) 1,129 (7) (3) 667 5 2
Shareholder Information
Annual General Meeting 27 April 2017
Announcement of half year and second quarter 2017 results 27 July 2017
Announcement of nine months and third quarter 2017 results 9 November 2017
Future dividends will normally be paid as follows:
First interim Announced with half-year and second-quarter results and paid in September
Second interim Announced with full-year and fourth-quarter results and paid in March
The record date for the first interim dividend for 2017, payable on 11 September 2017, will be 11 August 2017. Ordinary
Shares listed in London and Stockholm will trade ex-dividend from 10 August 2017. American Depositary Shares listed in New
York will trade ex-dividend from 9 August 2017.
Trademarks of the AstraZeneca group of companies and of companies other than AstraZeneca appear throughout this document in
italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of
companies. Trademarks of companies other than AstraZeneca that appear in this document include DuaklirGenuair, Duaklir,
Eklira, and Tudorza, trademarks of Almirall, S.A.; Toprol-XL, a trademark of Aralez Pharmaceuticals Inc. or AstraZeneca
(depending on geography); Epanova, a trademark of Chrysalis Pharma AG.; Synagis, owned by AstraZeneca or AbbVie Inc.
(depending on geography); Siliq, owned by Leo Pharma A/S or Valeant Pharmaceuticals Luxembourg S.á.r.l. (depending on
geography); and Zavicefta, a trademark of Pfizer Inc.
Addresses for Correspondence
Registered Office1 Francis Crick AvenueCambridge Biomedical Campus, CambridgeCB2 0AAUK Registrar andTransfer OfficeEquiniti LimitedAspect HouseSpencer RoadLancingWest SussexBN99 6DAUK Swedish Central Securities DepositoryEuroclear Sweden ABPO Box 191SE-101 23 StockholmSweden US DepositaryCitibank Shareholder ServicesPO Box 43077ProvidenceRI 02940-3077USA
Tel: +44 (0)20 3749 5000 Tel (freephone in UK): 0800 389 1580 Tel (outside UK): Tel: +46 (0)8 402 9000 Tel: (toll free in the US) +1 (888) 697 8018 Tel: (outside the US) +1 (781) 575 4555 citibank@shareholders-online.com
+44 (0)121 415 7033
Cautionary Statements Regarding Forward-Looking Statements
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act
1995, we are providing the following cautionary statement:
This document contains certain forward-looking statements with respect to the operations, performance and financial
condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or
other financial or other measures. Although we believe our expectations are based on reasonable assumptions, any
forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that
could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements
reflect knowledge and information available at the date of preparation of this document and AstraZeneca undertakes no
obligation to update these forward-looking statements. We identify the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could
cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond
our control, include, among other things: the loss or expiration of, or limitations to, patents, marketing exclusivity or
trademarks, or the risk of failure to obtain and enforce patent protection; effects of patent litigation in respect of IP
rights; the impact of any delays in the manufacturing, distribution and sale of any of our products; the impact of any
failure by third parties to supply materials or services; the risk of failure of outsourcing; the risks associated with
manufacturing biologics; the risk that R&D will not yield new products that achieve commercial success; the risk of delay
to new product launches; the risk that new products do not perform as we expect; the risk that strategic alliances and
acquisitions, including licensing and collaborations, will be unsuccessful; the risks from pressures resulting from generic
competition; the impact of competition, price controls and price reductions; the risks associated with developing our
business in emerging markets; the risk of illegal trade in our products; the difficulties of obtaining and maintaining
regulatory approvals for products; the risk that regulatory approval processes for biosimilars could have an adverse effect
on future commercial prospects; the risk of failure to successfully implement planned cost reduction measures through
productivity initiatives and restructuring programmes; the risk of failure of critical processes affecting business
continuity; economic, regulatory and political pressures to limit or reduce the cost of our products; failure to achieve
strategic priorities or to meet targets or expectations; the risk of substantial adverse litigation/government
investigation claims and insufficient insurance coverage; the risk of substantial product liability claims; the risk of
failure to adhere to applicable laws, rules and regulations; the risk of failure to adhere to applicable laws, rules and
regulations relating to anti-competitive behaviour; the impact of increasing implementation and enforcement of more
stringent anti-bribery and anti-corruption legislation; taxation risks; exchange rate fluctuations; the risk of an adverse
impact of a sustained economic downturn; political and socio-economic conditions; the risk of environmental liabilities;
the risk of occupational health and safety liabilities; the risk associated with pensions liabilities; the impact of
failing to attract and retain key personnel and to successfully engage with our employees; the risk of misuse of social
medial platforms and new technology; and the risk of failure of information technology and cybercrime. Nothing in this
presentation / webcast should be construed as a profit forecast.
This information is provided by RNS
The company news service from the London Stock ExchangeRecent news on AstraZeneca
See all newsRCS - LHH - LHH, EZRA's AI Leadership Transformation Program
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpoint in Bax24 Ph3 trial
AnnouncementREG - AstraZeneca PLC - Datroway improved OS and PFS in TROPION-Breast02
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Enhertu improved IDFS in early BC in DB-05
Announcement